Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion Therapeutics Stock Performance
NASDAQ:CYCN traded down $0.01 on Friday, reaching $0.90. The company's stock had a trading volume of 178,627 shares, compared to its average volume of 133,515. Cyclerion Therapeutics has a 1-year low of $0.46 and a 1-year high of $3.62. The firm has a market cap of $39.11 million, a PE ratio of -0.72 and a beta of 2.31. The business's 50-day moving average price is $0.70 and its two-hundred day moving average price is $0.88.
Cyclerion Therapeutics (NASDAQ:CYCN - Get Rating) last posted its earnings results on Wednesday, May 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06. Cyclerion Therapeutics had a negative return on equity of 99.04% and a negative net margin of 1,115.53%. The firm had revenue of $0.71 million during the quarter, compared to analysts' expectations of $0.55 million. As a group, sell-side analysts expect that Cyclerion Therapeutics will post -1.11 EPS for the current year.